logo
Share SHARE
FONT-SIZE Plus   Neg

Myriad Genetics Gets Rights To RAD51C Gene

Myriad Genetics, Inc. (MYGN) said Wednesday it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer.

In several studies, mutations in the RAD51C gene have been identified and associated with an increased risk for hereditary breast and ovarian cancer.

RAD51C was identified initially as a susceptibility gene for hereditary breast and ovarian cancer by members of the German Consortium for Hereditary Breast and Ovarian cancers in collaboration with pediatric hematologists and basic scientists predominantly located at the universities of Cologne, Dusseldorf and Munich.

Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Spanish fashion retailer Industria de Diseño Textil SA or Inditex reported Wednesday higher profit in its first half with strong like-for-like sales growth growth. EBITDA, a key earnings metric, improved 9 percent, while gross margin declined. Inditex shares were losing around 3 percent in the morning trading. Microsoft (MSFT) announced Wednesday that Xbox One X standard edition is now available to pre-order worldwide. The company said more than 130 games have now been enhanced for the system. Beginning today, the console, said to be the most powerful ever, can be booked from local retailers around the... German industrial conglomerate thyssenKrupp AG announced Wednesday that it has signed a memorandum of understanding or MoU with Tata Steel Ltd. about the combination of their European steel activities in a 50/50 joint venture. The companies expect up to 4000 job cuts in the joint venture.
comments powered by Disqus
Follow RTT